Gummadi J, Wang X, Xie C
J Hepatocell Carcinoma. 2023; 10:745-752.
PMID: 37215364
PMC: 10198173.
DOI: 10.2147/JHC.S406902.
Francisco A, Li J, Farghli A, Kanke M, Shui B, Munn P
Cancer Res Commun. 2023; 2(7):663-678.
PMID: 36923282
PMC: 10010304.
DOI: 10.1158/2767-9764.CRC-21-0177.
Abdelhamed W, El-Kassas M
World J Gastrointest Oncol. 2022; 14(6):1103-1114.
PMID: 35949219
PMC: 9244987.
DOI: 10.4251/wjgo.v14.i6.1103.
Narayan N, Requena D, Lalazar G, Ramos-Espiritu L, Ng D, Levin S
Stem Cell Reports. 2022; 17(8):1874-1888.
PMID: 35803261
PMC: 9391427.
DOI: 10.1016/j.stemcr.2022.06.003.
Hu J, Wang Y, Deng L, Yu H, Chen K, Bao W
Updates Surg. 2022; 74(5):1589-1599.
PMID: 35713784
DOI: 10.1007/s13304-022-01308-3.
Multiomic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma.
Francisco A, Kanke M, Massa A, Dinh T, Sritharan R, Vakili K
JCI Insight. 2022; 7(11).
PMID: 35482409
PMC: 9220943.
DOI: 10.1172/jci.insight.154743.
Imaging findings of hepatic epithelioid hemangioendothelioma and fibrolamellar hepatocellular carcinoma: a critical appraisal of current literature about imaging features of two rare liver cancers.
Mulazzani L, Alvisi M
Transl Cancer Res. 2022; 8(Suppl 3):S297-S310.
PMID: 35117109
PMC: 8797874.
DOI: 10.21037/tcr.2018.11.33.
Factors Influencing Overall Survival for Patients with Fibrolamellar Hepatocellular Carcinoma: Analysis of the Surveillance, Epidemiology, and End Results Database.
Polychronidis G, Feng J, Murtha-Lemekhova A, Heger U, Mehrabi A, Hoffmann K
Int J Gen Med. 2022; 15:393-406.
PMID: 35035232
PMC: 8754463.
DOI: 10.2147/IJGM.S338066.
Liver transplantation in malignant disease.
Lang S, Bednarsch J, Czigany Z, Joechle K, Kroh A, Amygdalos I
World J Clin Oncol. 2021; 12(8):623-645.
PMID: 34513597
PMC: 8394155.
DOI: 10.5306/wjco.v12.i8.623.
Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports.
Al Zahrani A, Alfakeeh A
J Med Case Rep. 2021; 15(1):132.
PMID: 33722275
PMC: 7962306.
DOI: 10.1186/s13256-021-02695-8.
Fibrolamellar hepatocellular carcinoma-related hyperammonemic encephalopathy: Up to now and next steps.
Canada Trofo Surjan R, Santana Dos Santos E, Silveira S, Makdissi F, Machado M
Clin Mol Hepatol. 2019; 26(2):231-232.
PMID: 31679315
PMC: 7160343.
DOI: 10.3350/cmh.2019.0084.
MicroRNA-21 as a diagnostic marker for hepatocellular carcinoma: A systematic review and meta-analysis.
Qu J, Yang J, Chen M, Cui L, Wang T, Gao W
Pak J Med Sci. 2019; 35(5):1466-1471.
PMID: 31489028
PMC: 6717466.
DOI: 10.12669/pjms.35.5.685.
Progression after Immunotherapy for Fibrolamellar Carcinoma.
Bauer U, Mogler C, Braren R, Algul H, Schmid R, Ehmer U
Visc Med. 2019; 35(1):39-42.
PMID: 31312648
PMC: 6597907.
DOI: 10.1159/000497464.
Spontaneous Rupture of Fibrolamellar Variant Hepatocellular Carcinoma.
Polavarapu A, Ahmed M, Samaha G, Weerasinghe C, Deeb L, Sokoloff A
Gastroenterology Res. 2019; 12(3):166-170.
PMID: 31236158
PMC: 6575133.
DOI: 10.14740/gr1148.
Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma.
Chakrabarti S, Tella S, Kommalapati A, Huffman B, Yadav S, Riaz I
J Gastrointest Oncol. 2019; 10(3):554-561.
PMID: 31183207
PMC: 6534717.
DOI: 10.21037/jgo.2019.01.35.
Structures of the PKA RIα Holoenzyme with the FLHCC Driver J-PKAcα or Wild-Type PKAcα.
Cao B, Lu T, Martinez Fiesco J, Tomasini M, Fan L, Simon S
Structure. 2019; 27(5):816-828.e4.
PMID: 30905674
PMC: 6506387.
DOI: 10.1016/j.str.2019.03.001.
The fusion landscape of hepatocellular carcinoma.
Zhu C, Wu L, Lv Y, Guan J, Bai X, Lin J
Mol Oncol. 2019; 13(5):1214-1225.
PMID: 30903738
PMC: 6487730.
DOI: 10.1002/1878-0261.12479.
High PKM2 expression is independently correlated with decreased overall survival in hepatocellular carcinoma.
Lu D, Lv W, Li W, Gao Y
Oncol Lett. 2018; 16(3):3603-3610.
PMID: 30127967
PMC: 6096177.
DOI: 10.3892/ol.2018.9100.
Precision oncology in liver cancer.
Sullivan K, Kenerson H, Pillarisetty V, Riehle K, Yeung R
Ann Transl Med. 2018; 6(14):285.
PMID: 30105235
PMC: 6068329.
DOI: 10.21037/atm.2018.06.14.
Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms.
Lalazar G, Simon S
Semin Liver Dis. 2018; 38(1):51-59.
PMID: 29471565
PMC: 6020845.
DOI: 10.1055/s-0037-1621710.
